Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
1032452-86-0Cn1cc(-c2ccnc(Cl)n2)c2ccccc21IIBWXYHPBMUNJP-UHFFFAOYSA-N1032452-86-0Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H302 (97.5%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 40 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Beschreibung3-(2-Chloropyrimidin-4-yl)-1-methylindole is a key intermediate in the synthesis of Osimertinib Mesylate. Osimertinib Mesylate (Trade Name: Tagrisso) is a targeted anticancer drug developed by AstraZeneca. It received marketing approval from the U.S. Food and Drug Administration (FDA) on November 13, 2015, and from the European Medicines Agency (EMA) on February 2, 2016, respectively. Later, it was also approved for marketing by the Pharmaceuticals and Medical Devices Agency (PMDA) of Japan on March 28, 2016. This medication is indicated for the treatment of non-small cell lung cancer (NSCLC) positive for the EGFR-T790M mutation.
Verwenden3-(2-chloropyriMidin-4-yl)-1-Methylindole is an ositinib intermediate that can be used to synthesise targeted therapeutics.